



**InmuneBio**

# HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM

Modulating Innate Immune Responses Against Disease

## INMUNE BIO INC. (NASDAQ: INMB)

We are a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient's innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer's disease and LIVNate™ targets nonalcoholic steatohepatitis (NASH). Inmune Bio's product platforms utilize a precision therapy approach, promoting the body's innate immune response to treat unsolved problems in medicine.

INMB has two product platforms with novel approaches to inflammation, neurodegenerative disease and oncology. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform focuses on neuroinflammation as a cause of neurodegenerative diseases, inflammation as a driver of NASH and inflammation in cancer and the Tumor Microenvironment (TME). The Immune Priming Platform focuses on signaling Natural Killer (NK) cells to help clear minimal residual disease in cancer.


## WHY FOCUS ON THE INNATE IMMUNE SYSTEM

Our body's immune system is broken into two components, innate and adaptive immune system. The adaptive immune system includes T and B cells. The Innate immune system consists of myeloid and NK cells and is the first line of immunological defense. The Adaptive and Innate immune system must work together to battle disease. INMB is focused exclusively on cells on the Innate immune system including Hepatic Stellate Cells, Myeloid Derived Suppressor Cells, NK cells and microglial cells.

**Dysfunction of the INNATE IMMUNE system can cause multiple diseases. When the INNATE IMMUNE SYSTEM IS DYSFUNCTIONAL, the power of immunotherapy is hindered, and it can wreak havoc on the host. INMB is focused on modulating the innate immune system to treat diseases.**

## SNAPSHOT AS OF JAN. 10, 2020

PRICE	S/O SHARES
<b>\$5.78</b>	<b>10.8</b>
MARKET CAP	DEBT
<b>~\$60 M</b>	<b>\$0</b>
52-WEEK RANGE	AVG. VOLUME
<b>\$3.50 - \$11.50</b>	<b>~20,000</b>
INSIDE OWNERSHIP	COVERAGE
<b>50%</b>	<b>Roth/Maxim/HCW</b>



## TARGETED DISEASES AND CONDITIONS OF OUR THERAPIES

CELL	PURPOSE	CONDITIONS	THERAPY
<b>Hepatic Stellate Cell</b>	HSCs recruit inflammatory and immune cells by producing specific cytokines and chemokines. Stellate cells are responsive to hepatic injury induced by variety of hepatic necrogenic agents.	Nonalcoholic Steatohepatitis (NASH)	<b>LIVNate™</b>
<b>Myeloid-Derived Suppressor Cells</b>	MDSC are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity.	Resistance to Immunotherapy	<b>INB03™</b>
<b>Microglia</b>	Microglia function is tightly regulated by the CNS microenvironment, and increasing evidence suggests that disturbances, such as neurodegeneration and ageing, can have profound consequences for microglial phenotype and function.	Neuro-Inflammation	<b>XPro1595™</b>
<b>Natural Killer Cells</b>	NK cells are an innate immune cell that can kill tumor cells or cells infected with a virus. NK cells play an important role in the immune surveillance of cancer.	Residual Disease	<b>INKmune™</b>

## OUR PIPELINE AND PROGRESS TO DATE

DN-TNF PLATFORM	DISEASE FIELD	PRE-CLINICAL	PHASE I	PHASE II (POC)	PIVOTAL
<b>INB03™</b>	Trastuzumab Resistance ONCOLOGY	██████████	██████████	██████████	
<b>LIVNate™</b>	NASH GI	██████████	██████████	██████████	
<b>XPro1595™</b>	Alzheimer's Disease CNS	██████████	██████████		
DN-TNF PLATFORM	DISEASE FIELD	PRE-CLINICAL	PHASE I	PHASE II (POC)	PIVOTAL
<b>INKmune™</b>	Ovarian CANCER	██████████	██████████		
<b>INKmune™</b>	Myelodysplastic Syndrome ONCOLOGY	██████████	██████████		

## OUR DEVELOPMENT PROGRESS



### Phase 1: Open-Label, Dose-Escalation Trial Completed

11 patients with advanced solid tumors with biomarkers of inflammation

- 3 dose levels of INB03 sub-cutaneous once a week
- All goals met 1) safe and well tolerated; 2) Phase II dose defined; 3) pharmacodynamic effect demonstrated

### Phase 2: Combination Trial in Patients with Cancer

#### Proof-of-Concept trial of INB03+Immunotherapy

- Treatment: Immunotherapy versus INB03+immunotherapy / Endpoints: Improved efficacy in combination therapy arm



### Phase IIa: Open-Label Trial

20 patients – No Control Group Patients with F2/3 NASH by non-invasive studies with >10% fat in liver. Treatment with LIVNate™ 1mg/kg SQ for 12 weeks PIFF and non-invasive biomarkers at 0, 6 and 12 weeks. Open label so biomarkers “visible” at 6-week time point

#### EXPECTED RESULTS

- Decrease in liver fat
- Improvement in liver function tests
- Improvement in insulin resistance



### Phase 1: Biomarker directed trial of patients with inflammation and proven Alzheimer's disease

18 patients in three (3) dosing cohorts - Weekly XPro1595 subQ for 3 months - Biomarkers of inflammation at 0, 6 and 12 weeks

#### ENDPOINTS : Safety

- Decreased inflammation blood, cerebrospinal fluid (CSF), brain (white matter free water by MRI) and breath (breath volatile organic compounds)
- Measures of cogitation, psychiatric symptoms and quality of life (QOL)



### Phase 1 Clinical Trial

10 patients with high-risk MDS treated with INKmune therapy by intravenous

#### EXPECTED RESULTS

- Demonstrate safety of intravenous INKmune therapy in elderly patients
- Put chemo-resistant disease into remission
- Prolonged remissions with excellent quality of life

## SIGNIFICANT UPCOMING CATALYSTS

PRODUCT	GEOGRAPHY	INDICATION	EVENT	TIMELINE
INB03	Australia	Solid Tumors	Reported Positive Preliminary Data from Phase I	August '19
INKmune	UK	Ovarian Cancer	Initiate Enrollment of Phase 1 study	2H'20
INB03	Australia	Solid Tumors	Initiate INB03 Combination Phase 2 Study in Cancer	2H'20
INKmune	UK	MDS	Initiate Enrollment of Phase 1 study	2H'20
XPro1595	Australia	Alzheimer's	Initiate Enrollment of Phase 1 Study	Q4'19
LIVNate	Australia	NASH	Initiate LIVNate Phase II Nash trial	2H'20
XPro1595	Australia	Alzheimer's	Early Data	2H'20
INB03	Australia/US	Solid Tumors	Initiate INB03 combination immunotherapy Phase 2 Study	2H'20

## MANAGEMENT

**Raymond J. Tesi, MD**  
CEO/CMO & Chairman

**David J. Moss**  
CFO

**Mark W. Lowdell, PhD**  
CSO

**Christopher J. Barnum, PhD**  
Director of Neuroscience

**Joshua S. Schoonover, Esq.,**  
Assoc. General Counsel

**Mr. David Moss**  
INmune Bio Inc. (NASDAQ: INMB)  
David Moss, Chief Financial Officer  
PH: (858) 964-3720  
[Dmoss@INmuneBio.com](mailto:Dmoss@INmuneBio.com)

#### Information about Forward-Looking Statements

This fact sheet may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company's filings with the SEC. The occurrence of any of these risks and uncertainties could have a material adverse effect on the company's business, financial condition, and results of operations. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss, or even complete loss of investment. Past performance is not indicative of future results. Clinical trials are in early stages. For additional disclosure regarding risks faced by INmune Bio, Inc., please see our public filings with the Securities and Exchange Commission, available on the Investors section of our website at [www.INmuneBio.com](http://www.INmuneBio.com) and on the SEC's website at [www.SEC.gov](http://www.SEC.gov).